<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03999528</url>
  </required_header>
  <id_info>
    <org_study_id>Rheu-med.9med.research</org_study_id>
    <nct_id>NCT03999528</nct_id>
  </id_info>
  <brief_title>14-3-3η Protein, Disease Activity and Bone Mineral Density, in Female Patients With Rheumatoid Arthritis</brief_title>
  <official_title>14-3-3η Protein, Disease Activity and Bone Mineral Density, in Female Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Azhar University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Al-Azhar University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Is to investigate the relation between 14-3-3η protein, disease activity, and bone mineral
      density in female patients with rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: all patients in the study will subject to:

        -  Clinical assessment, WT, Height ,BMI, parity, medications,

        -  DAS 28.

        -  Serum 14-3-3η protein.

        -  DEXA scan.

      Grouping:

        -  Group I: RA Patients with low BMD.

        -  Group II: RA Patients with normal BMD.

        -  Group III: normal control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>14-3-3η Protein and RA disease activity</measure>
    <time_frame>three months</time_frame>
    <description>percent of active RA disease and study the correlation between 14-3-3η Protein and RA disease activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>14-3-3η Protein and osteoporosis in RA patients</measure>
    <time_frame>three months</time_frame>
    <description>percent of low BMD and study the correlation between 14-3-3η Protein and osteoporosis in RA patients</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">45</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <description>RA Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>normal control</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>14-3-3η Protein assay</intervention_name>
    <description>blood sampling for assessment of serum 14-3-3η Protein</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with rheumatoid arthritis attending the Rheumatology department, at Al-Azhar
        faculty of medicine from May 2019 to August 2019
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatoid arthritis according to ACR 2010 criteria with at least one year duration.

          -  Premenopausal females.

          -  On conventional DMARD with maximum 5 mg steroids.

        Exclusion Criteria:

          -  Biological treatment.

          -  Previous antiresorptive treatment, or bone anabolics.

          -  High dose corticosteroid.

          -  Chronic renal or kidney disease.

          -  Medications affecting bone metabolism.

          -  Thyroid or adrenal dysfunction,
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED ABOGAMAL</last_name>
    <role>Study Chair</role>
    <affiliation>Al-Azhar Faculty of medicine- Cairo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Al-Azhar Faculty of medicine, Rheumatology Department</name>
      <address>
        <city>Cairo</city>
        <zip>11311</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 7, 2020</last_update_submitted>
  <last_update_submitted_qc>June 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al-Azhar University</investigator_affiliation>
    <investigator_full_name>Ahmed Abogamal</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>14-3-3η Protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

